ALZHEIMER S DISEASE
Clinical trials for ALZHEIMER S DISEASE explained in plain language.
Never miss a new study
Get alerted when new ALZHEIMER S DISEASE trials appear
Sign up with your email to follow new studies for ALZHEIMER S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Alzheimer's drug trial halted early – no breakthrough yet
Disease control TerminatedThis study tested an experimental drug called SHR-1707 in people with mild memory problems or mild Alzheimer's disease. The goal was to see if it could safely reduce harmful protein clumps in the brain. The trial was stopped early, and it is not expected to cure the disease.
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Alzheimer's drug TB006 safety study halted early
Disease control TerminatedThis study looked at the long-term safety of an experimental drug called TB006 (oloctinebart) in people with Alzheimer's disease. It included 119 participants who had either completed a previous TB006 study or were new to the drug. The study was terminated early, so the full safe…
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: TrueBinding, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Alzheimer's drug AL002 safety trial ends early
Disease control TerminatedThis study was a long-term extension of an earlier trial, testing the safety and tolerability of AL002 in 197 people with early Alzheimer's disease. Participants received the drug by IV infusion. The trial was terminated, meaning it stopped before completion, so the full safety a…
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Alzheimer's drug SPG302 safety study ends early
Disease control TerminatedThis study aimed to check the long-term safety and effects of a daily pill called SPG302 in people with mild-to-moderate Alzheimer's disease. It included 12 participants who had already been in a previous SPG302 study. The study was terminated early, so results are limited.
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief TerminatedThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC